JUNSHI BIO (01877) shares are soaring 5.11% in Friday's trading session, reaching HK$26.06 with a trading volume of HK$59.43 million. The significant uptick comes on the heels of the company's recently announced financial results for the first three quarters of 2025.

The biopharmaceutical company reported impressive figures for the period, with revenue climbing 42.06% year-on-year to RMB 1.806 billion. More notably, JUNSHI BIO has managed to narrow its net loss attributable to shareholders by 35.7% to RMB 596 million, translating to a basic loss per share of RMB 0.60. This substantial improvement in financial performance appears to be driving investor optimism.

At the heart of JUNSHI BIO's growth is the strong sales performance of its core product, Toripalimab (brand names: Tuoyi®/LOQTORZI®). The drug generated domestic sales of approximately RMB 1.495 billion, marking a robust 40% increase compared to the same period last year. The company's "efficiency enhancement and shareholder return" initiative, which includes cost-control measures and resource optimization, has played a crucial role in reducing losses and improving overall financial health.

Adding to the positive sentiment, JUNSHI BIO reported a strong liquidity position with cash and tradable financial assets totaling RMB 3.27 billion as of the end of the reporting period. This healthy cash reserve provides the company with ample resources to fund its ongoing operations and future growth initiatives, further bolstering investor confidence in its long-term prospects.